Novo Nordisk, the global leader in diabetes care, on Friday launched Ryzodeg® for people with type 2 diabetes in Bangladesh with a view to providing first in its class treatment and safety for patients, agency reports. Ryzodeg® is a combination of two distinct insulin analogues (insulin degludec and insulin aspart at a ratio of 70% and 30%), making it the first combination of a basal insulin with an ultra-long duration of action and a well-established mealtime insulin in one pen.
Ryzodeg® offers successful reductions in blood glucose with lower risk of hypoglycaemia compared to conventional insulins for adults with type 2 diabetes. As Ryzodeg® is a combination product it requires fewer daily injections than administering basal and mealtime insulin in separate injections. People with diabetes currently using basal-bolus regimens may need to take up to four daily injections, which can be inconvenient and stressful.
“Ryzodeg® provides successful glycaemic control, fewer injections and reduced rates of hypoglycaemia compared to basal-bolus regimens,” according to top healthcare professionals. Maziar Doustdar said Bangladesh has close to 5.9 million people with diabetes and the figure is expected to be doubled by 2030. “We are focused at providing quality medications that will help health care professionals to meet the demands and challenges of diabetes in Bangladesh.”
He said they are extremely pleased to have introduced Ryzodeg reinforcing their commitment to provide best of healthcare solutions for the use of doctors in Bangladesh. “Novo Nordisk has always been striving to develop products that address key challenges faced by people with diabetes and physicians. For more than 90 years, Novo Nordisk has been leading the fight against diabetes by developing the most innovative products based on patient needs,” said Camilla Sylvest.
Rajan Kumar said Ryzodeg is an innovative product that will give the health care professional a better way to manage the condition. In a country like Bangladesh where diabetes has become one of the biggest healthcare challenges, it is critical that product innovations are aimed at assisting physicians to provide better and effective treatment options, he said. Ryzodeg is expected to help people with diabetes whose were dependent on separate basal and bolus injections in improving their quality of life, said Dr. Mohammad Saiful, head of marketing, Novo Nordisk Pharma (Pvt.) Ltd.
However, it is important to note that patients must consult their doctor and strictly follow their advice about any change in their treatment as this product has to be prescribed by a qualified physician, Saiful added. Novo Nordisk has long-lasting partnership with Transcom Distribution Company Limited (TDCL) since 2006. It is the importer and distributor of Novo Nordisk insulin Bangladesh. Novo Nordisk produce human insulin vial at high-tech manufacturing plant at Eskayef Bangladesh, the fastest growing pharmaceutical company in Bangladesh.